Next 10 |
home / stock / glpg / glpg articles
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present encouraging new d...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR ...
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that its Boar...
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announces that all resolutions proposed at the c...
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymph...
Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:GLPG) to underperform, citing few catalysts in the near term. Gal...
Publication of annual report for financial year 2023 Annual Shareholders' Meeting resolutions include approval of revised Remuneration Polic...
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 26 March 20...
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current f...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...
2024-05-11 10:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...